期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

c-kit基因在急性非淋巴细胞白血病患者的表达及临床意义 被引量：5

原文传递
导出
作者 陈烨 许利华 董志珍 邵苏吉 陈瑞新 吴芳颐
机构地区 南通医学院附属医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2003年第3期161-162,共2页 Chinese Journal of Hematology
基金 江苏省自然科学基金资助项目 (BK 99161)
关键词 C-KIT基因 急性非淋巴细胞白血病 基因表达
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Lu L;Heinrich MC;Wang LS.Retroviral-mediated gene transduction of c-kit into single hematopoietic progenitor cells from cord blood enhances erythroid colony formation and decreases sensitivity to inhibition by tumor necrosis factor-α and transforming growth factor-β1,1999.
  • 2许文林,陈道明,张永宁,吴朝阳.急性白血病体外药敏试验MTT法的初步探讨[J].实用癌症杂志,1998,13(1):32-33. 被引量：1
  • 3许利华,吴芳颐,陈烨.c-kit在血液病中的表达[J].交通医学,2001,15(1):16-17. 被引量：2
  • 4Longley BJ;Reguera MJ;Ma Y.Classed of c-kit activating mutation:proposed mechanisms of action and implications for disease classification and therapy[J],2001.
  • 5Bene MC;Bernier M;Casasnovas RO.The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias,1998.

二级参考文献2

共引文献1

同被引文献37

  • 1Drexler H G,Meyer C,Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells [J]. Leukemia, 1999,33( 1 ) :83-91.
  • 2Ozeki K,Kiyoi H,Hirose Y,et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia [ J ]. Blood, 2004, 103 (5) : 1801-1908.
  • 3Oka T, Yoshino T, Hayashi K, et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with DNA expression array and tissue microarray[J]. Am J Pathol,2001,159(4):1495-1505.
  • 4Kozlowski M,Larose L,Lee F,et al. SHP-1 binds and negatively modulates the c-kit receptor by interaction with tyrosine 569 in the c-kit juxtamembrane domain [J]. Mol Cell Biol, 1998,18 (4) : 2089-2099.
  • 5Kelly LM,Gilliland DG.Genetics of myeloid Leukemias.Annu Rev Genomics Hum Genet,2002,3(42):179-198.
  • 6Bloom Field CD,Law Rence D,By rd JC,et al.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subgroup.Cancer Res,1998,58(18):4173-4179.
  • 7Byrd JC,Mrzek K,Dodge RK,et al.Pretreatment cytogenetic abnormalities are predictive of induction success,cumulative incidence of relapse,and overall survival in adult patients with denovoacu tem yeloid leukemia:results from Cancer and Leukemia Group B (CALGB 8461).Blood,2002,100(13):4325-4336.
  • 8Grimwade D,Walker H,Oliver F,et al.The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered in to the MRC AM L 10 trial The Medical Research Council Adult and Childrens Leukemia Working Parties.Blood,1998,92(7):2322-2333.
  • 9Schlenk RF,Benner A,Hartmann F,et al.Risk-adapted post remission therapy in acute myeloid leukemia:results of the Germ an Multi center AM L HD93 treatment trial.Leukemia,2003,17(8):1521-1528.
  • 10Rosnet O,Marchetto S,delapeyriere O,et al.Murine Fit3,a gene en-coding a novel tyrosine kinase recepeor of the PDGFR/CSF1 R family.Oncogene,1991,6(9):1641-1650.

引证文献5

二级引证文献14

中华血液学杂志
2003年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部